Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company de...
HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 p...
The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigati...
HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and raises the price...
Acurx Pharmaceuticals (NASDAQ:ACXP) reported Q2 EPS $(1.89) Up from $(5.21) YoY
